ROBOTICS & AUTOMATION
Empowering Progress
Up to 25% off Essentials Robotics and Automation titles
International Review of Neurobiology
- 1st Edition, Volume 42 - January 23, 1998
- Editors: Ronald J. Bradley, Robert Adron Harris, Peter Jenner
- Language: English
- Hardback ISBN:9 7 8 - 0 - 1 2 - 3 6 6 8 4 2 - 4
- Paperback ISBN:9 7 8 - 0 - 1 2 - 3 9 1 8 1 6 - 1
- eBook ISBN:9 7 8 - 0 - 0 8 - 0 8 5 7 7 6 - 3
Volume 42 presents an in-depth review on Alzheimer's Disease as well as a look at several transcription… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteVolume 42 presents an in-depth review on Alzheimer's Disease as well as a look at several transcription factors.
- Clinical features of stroke and the current stasis of stroke therapy
- Alzheimers Disease--pathology, pathological proteins, etiology, pathogenesis, neurotransmitter alterations, and treatment strategies
- An examination of the regulation of AP-1 and related transcription factors and their role in brain injury and drug abuse-related behavior
- Emerging roles of the transcription factor NF(B
- Recent advances about the nature of alterations in ion channel structure or function which may be responsible for epileptogenesis
- An integrated model accounting for the multiple mechanisms involved in the posttranslational regulation of glutamate ionotroic receptors
- Genetic mutation and the Glycine Receptor
Researchers and graduate students in neuroscience, genetics of cells, pharmacology, biology, and physiology
M.A. Smith, Alzheimer Disease
W.D. Dietrich, Neurobiology of Stroke
M.P. Mattson, Free Radicals, Calcium, and Synaptic Plasticity-Cell Death Continuum: Emerging Roles of the Transcription Factor NFkB
K. Pennypacker, AP-1 Transcription Factors: Short- and Long-Term Modulators of Gene Expression in the Brain
I. Mody, Ion Channels in Epilepsy
X. Bi, S. Standley, and M. Baudry, Posttranslational Regulation of Ionotropic Glutamate Receptors and Synaptic Plasticity
B. Vafa and P.R. Schofield, Heritable Mutations in the Glycine, GABAA, and Nicotinic Acetycholine Receptors Provide New Insights into the Ligand-Gated Ion Channel Receptor Superfamily
- No. of pages: 345
- Language: English
- Edition: 1
- Volume: 42
- Published: January 23, 1998
- Imprint: Academic Press
- Hardback ISBN: 9780123668424
- Paperback ISBN: 9780123918161
- eBook ISBN: 9780080857763
RB
Ronald J. Bradley
Affiliations and expertise
Louisiana State University Medical Center, School of Medicine, Baton Rouge, U.S.A.RH
Robert Adron Harris
Affiliations and expertise
University of Texas, Austin, U.S.A.PJ
Peter Jenner
Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinson’s disease. He has spent the major part of his career at King’s College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of King’s College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.
Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinson’s disease patient-carer groups across the UK.
Affiliations and expertise
Emeritus Professor of Pharmacology, Institute of Pharmaceutical Sciences, King’s College London, London, UKRead International Review of Neurobiology on ScienceDirect